Fundamental Analysis of SAGIMET BIOSCIENCES INC-A(NASDAQ:SGMT) stock

Fundamental Rating

Overall SGMT gets a fundamental rating of 4 out of 10. We evaluated SGMT against 568 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for SGMT as it has an excellent financial health rating, but there are worries on the profitability. SGMT has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year SGMT has reported negative net income.

SGMT had a negative operating cash flow in the past year.

In the past 5 years SGMT always reported negative net income.

SGMT had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With an excellent Return On Assets value of -15.95%, SGMT belongs to the best of the industry, outperforming 81.42% of the companies in the same industry.

With an excellent Return On Equity value of -16.33%, SGMT belongs to the best of the industry, outperforming 87.96% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-15.95%
ROE	-16.33%
ROIC	N/A

ROA(3y)-54.19%

ROA(5y)-61.37%

ROE(3y)-61.4%

ROE(5y)-72.43%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SGMT so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for SGMT has been increased compared to 1 year ago.

There is no outstanding debt for SGMT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 26.29 indicates that SGMT is not in any danger for bankruptcy at the moment.

SGMT has a Altman-Z score of 26.29. This is amongst the best in the industry. SGMT outperforms 94.69% of its industry peers.

There is no outstanding debt for SGMT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	26.29

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

SGMT has a Current Ratio of 38.41. This indicates that SGMT is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of SGMT (38.41) is better than 99.11% of its industry peers.

A Quick Ratio of 38.41 indicates that SGMT has no problem at all paying its short term obligations.

SGMT has a better Quick ratio (38.41) than 99.11% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	38.41
Quick Ratio	38.41

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for SGMT have decreased strongly by -87.67% in the last year.

EPS 1Y (TTM)-87.67%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-28.57%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

SGMT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.61% yearly.

SGMT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 124.02% yearly.

EPS Next Y90.09%

EPS Next 2Y32.6%

EPS Next 3Y19.21%

EPS Next 5Y11.61%

Revenue Next Year-100%

Revenue Next 2Y-41.42%

Revenue Next 3Y-25.99%

Revenue Next 5Y124.02%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

SGMT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SGMT. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

SGMT's earnings are expected to grow with 19.21% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y32.6%

EPS Next 3Y19.21%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

SGMT does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SAGIMET BIOSCIENCES INC-A

NASDAQ:SGMT (12/18/2024, 1:44:00 PM)

5.89

-0.05 (-0.84%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap189.66M

Analysts

Price Target

Short Float %

Short Ratio

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-15.95%
ROE	-16.33%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.01

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	38.41
Quick Ratio	38.41
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-87.67%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y90.09%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

SAGIMET BIOSCIENCES INC-A (SGMT)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens